Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CSN5i-3 is a novel potent oral and selective CSN5/Jab1 inhibitor that inhibits CSN-catalyzed Cul1 deneddylation with an IC50 value of 5.8 nM.CSN5i-3 exhibits anticancer activity, inhibits cell proliferation and induces apoptosis in human breast cancer cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 378.00 | |
5 mg | In stock | $ 813.00 | |
10 mg | In stock | $ 1,230.00 | |
25 mg | In stock | $ 1,830.00 | |
50 mg | In stock | $ 2,470.00 | |
100 mg | In stock | $ 3,330.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 886.00 |
Description | CSN5i-3 is a novel potent oral and selective CSN5/Jab1 inhibitor that inhibits CSN-catalyzed Cul1 deneddylation with an IC50 value of 5.8 nM.CSN5i-3 exhibits anticancer activity, inhibits cell proliferation and induces apoptosis in human breast cancer cells. |
Targets&IC50 | CSN5:5.8 nM |
In vitro | CSN5i-3, by trapping CRLs in the neddylation state, effectively causes the inactivation of a specific subset of CRLs through the induction of degradation in their substrate recognition module.[1] |
In vivo | CSN5i-3 exhibits a favorable pharmacokinetic profile, and its application results in the formation of cleaved PARP and cleaved caspase 3, indicating the initiation of apoptosis.[1] |
Molecular Weight | 505.56 |
Formula | C28H29F2N5O2 |
CAS No. | 2375740-98-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75.83 mg/mL (150 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CSN5i-3 2375740-98-8 Apoptosis Others CSN5i3 CSN-5i-3 CSN5i 3 inhibitor inhibit